Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $11.5 million.

  • Mangoceuticals' Shares Outstanding (Weighted Average) rose 47225.15% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 47225.15%. This contributed to the annual value of $2.0 million for FY2024, which is 8422.66% up from last year.
  • According to the latest figures from Q3 2025, Mangoceuticals' Shares Outstanding (Weighted Average) is $11.5 million, which was up 47225.15% from $7.3 million recorded in Q2 2025.
  • Mangoceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $15.8 million for Q2 2023, and its period low was $1.1 million during Q3 2023.
  • Over the past 3 years, Mangoceuticals' median Shares Outstanding (Weighted Average) value was $2.0 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first plummeted by 8896.82% in 2024, then surged by 47225.15% in 2025.
  • Quarter analysis of 3 years shows Mangoceuticals' Shares Outstanding (Weighted Average) stood at $1.1 million in 2023, then soared by 84.23% to $2.0 million in 2024, then soared by 482.34% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $7.3 million for Q2 2025, and $4.6 million during Q1 2025.